Keystone Meeting on Cancer Immunotherapy Beyond Immune Checkpoint Blockade and Overcoming Resistance in Vancouver, Canada. “High Labyrinthin Expression is Associated with High PDL-1 Expression and Poor Prognosis in Patients with NSCLC”, March 2024.

Society for Immunotherapy of Cancer meeting, Nov 2023:

1. “Labyrinthin as a potential neoantigen for oncogene-driven and non-oncogene-driven lung adenocarcinomas”; confirms labyrinthin as a diagnostic marker and a therapeutic target and reports on the novel finding that the more labyrinthin is expressed on tumors, the more that the immune checkpoint receptor, PDL-1, is expressed. The results validate Phase II clinical trial using a PDL-1 blocker (pembrolizumab) with our vaccine, LabVax.  See Full Article Here.

2. “Novel biomarker assays for detecting labyrinthin-positive adenocarcinomas for a phase I/II trial of peptide vaccine LabVax 3(22)-23 alone or in combination with pembrolizumab”, sets that stage for the Phase II trial using LabVax and immune checkpoint inhibitor combination.  See Full Article Here.

3. “A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas”; describes the clinical trial.  See Full Article Here.

14th Annual World Cancer Congress in Barcelona, Spain.  “Labyrinthin:  From bench-to-clinic as neo-and pan-adenocarcinoma target.” July 2023.

Li, et al. A first-in-human phase I trial of a novel peptide vaccine LabVax 3(22)-23 and adjuvant GM-CSF sargramostim in patients with refractory labyrinthin-expressing adenocarcinomas. ASCO/Journal of Clinical Oncology 2023.

LabyRx is one of the highlighted companies at MedInvest (New York City) via National Cancer Institute
invitation; December 2022.

LabVax was selected for a special oral presentation entitled “Novel Peptide Vaccines against Labyrinthin
for Adenocarcinomas” that was given by a lead researcher at the UCD NIH-Designated Comprehensive
Cancer Center.  October 2022.

“High Labyrinthin Expression is Associated with Poor Prognosis in Patients with NSCLC” shared a novel,
yet expected, study result in which labyrinthin expression is directly related to patient morbidity (i.e.,
death). The work presented by a team of UCD investors supports the idea that labyrinthin is more than
a marker, but important to screen patients for anti-labyrinthin treatment, predict patient outcomes (Dx)
and serve as a key target in strategizing an attack on adenocarcinomas. October 2022.

W Ma, et al. A First-In-Human Phase I open-label study of a novel cancer vaccine LabVax 3(22)-23 and adjuvant GM-CSF in patients with advanced stage adenocarcinomas. American Society for Clinical Oncology (ASCO) 2022.

M Babich, T Li, JA Radosevich. Generation of peptide vaccines targeting labyrinthin, a pan-adenocarcinoma biomarker.  American Association for Cancer Research (AACR), 2020.

Saleeve, et al. Anti-labyrinthin monoclonal antibody reduces human adenocarcinoma circulating tumor cells in the blood of patient-derived xenograft models and inhibits the growth of adenocarcinoma cell cultures. AACR, 2019.